International Conference and Exhibition on Pharmaceutical Regulatory Affairs 2016

OMICS Group invites all the participants across the globe to attend the 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR during September 12-14, 2016 San Antonio, USA with the theme of Share and Enhance the Aspects on Novel Policies in Regulatory Affairs. Regulatory Affairs 2016 has been exceptionally formulated with novel topics like Best Industry Practices, Regulatory Requirements for Pharmaceuticals, Intellectual Property Management and Novel Strategies for Growth in the Pharma and Regulatory Affairs.

Regulatory Affairs department is the strength of Pharmaceutical Industry. It is the revenue generator for pharmaceutical Industry. The Regulatory Affairs department is an important part of the pharmaceutical companies. More than 15 years span is required to develop and launch a new pharmaceutical product in the market. The Regulatory Affairs Agencies explains expenditure spent on each drug annually is $850 million in US. The Indian Pharmaceutical industry is one of the fastest growing industries in India, with a compounded annual growth rate (CAGR) of over 13 % in last 5 years and it is expected to grow at a higher rate in coming 10 years India spends around $300 million, united kingdom $700 million, Brazil $200 million, France $550 million, Italy $400 million. As per cabinet decision in June 2010 in Japan amended a new policy i.e., Health power strategy through “Life Innovation” and expenditure spent on each drug was $450 million. Internally it cooperates with other department like drug development, manufacturing, marketing and clinical research. Externally, it is the key interface between the company and the regulatory authorities. Industrialized regulatory affairs are to drive compliance, speed to market, and cost efficiency.